Curriculum Vitae

DR. SRI KISHA A/P SUBRAMANIAM

Medical Lecturer
  • Department Clinical Oncology
    Faculty of Medicine
  • kisha.sri
  • 0379677022

ACADEMIC QUALIFICATION

  • M. (CLINICAL ONCOLOGY), (Clinical Oncology)
    Universiti Malaya (UM)
  • BACHELOR (MEDICAL DOCTOR), (MEDICAL DOCTOR)
    Universitas Padjadjaran

ADMINISTRATIVE DUTIES

  • Programme Coordinator
    03 Jun 2025 - present (Department of Oncology Clinical, Faculty of Medicine)
  • Clinical Administration
    01 Jun 2025 - 31 Dec 2026 (Department)
  • Project Leader
    01 Jun 2025 - 31 Dec 2026 (University Malaya)
  • Task Force Leader
    04 Sep 2025 - 03 Mar 2026 (National)
  • Chief of Internal Auditor
    01 Jun 2025 - 31 Oct 2025 (University Malaya)
  • Clinical Administration
    22 Aug 2025 - 24 Aug 2025 (Department)

MEMBERSHIPS

  • MEMBER OF EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY, MEMBER
    2025 to 2026 (International)
  • MEMBER OF ACADEMY OF MEDICINE MALAYSIA (AMM), MEMBER
    Since 2024 (National)
  • MEMBER OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY, MEMBER
    2023 to 2026 (International)
  • MALAYSIAN ONCOLOGICAL SOCIETY (MOS), MEMBER
    Since 2022 (National)
  • ESMO, THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY,, MEMBER
    2018 to 2026 (International)
  • MEMBER OF THE INTERNATIONAL SOCIETY OF PEDIATRIC ONCOLOGY (SIOP), MEMBER
    2024 to 2025 (International)

PUBLICATIONS

Other Publications
  1. Clinical Practice Recommendations (CPR) :A Global Childhood Cancer Supportive Care Collaboration Version 1.4.1 July 2025 Literature review current through: March 2023 | This topic last updated: July 14, 2025 - Policy Paper
  2. Rozita.A.M, Sri Kisha. S, Zulaikha.J, Hoong, N (2035). Guidelines on Brachytherapy ( Intrauterine brachytherapy/ Full insertion)[Policy brief]. University Malaya - Policy Paper

RESEARCH PROJECT

National
  1. 2021 - 2026, ARCUS BIOSCIENCES, INC.
    A PHASE 3 STUDY TO EVALUATE ZIMBERELIMAB (AB122) MONOTHERAPY COMPARED TO STANDARD CHEMOTHERAPY OR ZIMBERELIMAB COMBINED WITH AB154 IN FRONT-LINE, PD-L1-POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER ( Principal Investigator(PI))
  2. 2020 - 2024, National Cancer Centre of Singapore
    Single-arm, open-label, Phase 2 study of dacomitinib with or without dose titration for the First-line treatment of locally meta-static non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation ( Principal Investigator(PI))
Private
  1. 2025 - 2035, ASTRAZENECA SDN. BHD.
    A PHASE III, RANDOMISED, OPEN-LABEL, GLOBAL STUDY OF ADJUVANT DATOPOTAMAB DERUXTECAN (DATO-DXD) IN COMBINATION WITH RILVEGOSTOMIG OR RILVEGOSTOMIG MONOTHERAPY VERSUS STANDARD OF CARE, FOLLOWING COMPLETE TUMOUR RESECTION, IN PARTICIPANTS WITH STAGE I ADENOCARCINOMA NON-SMALL CELL LUNG CANCER WHO ARE CTDNA-POSITIVE OR HAVE HIGH-RISK PATHOLOGICAL FEATURES (TROPION-LUNG12) ( Co-Researcher)
  2. 2025 - 2032, BRISTOL-MYERS SQUIB
    A RANDOMIZED, DOUBLE-BLIND, MULTICENTER PHASE 3 TRIAL OF BMS-986489 (BMS-986012 + NIVOLUMAB FIXED DOSE COMBINATION) IN COMBINATION WITH CARBOPLATIN PLUS ETOPOSIDE VS ATEZOLIZUMAB IN COMBINATION WITH CARBOPLATIN PLUS ETOPOSIDE AS FIRST-LINE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (TIGOS ( Principal Investigator(PI))
  3. 2025 - 2029, GILEAD SCIENCES, INC.
    A GLOBAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS STANDARD OF CARE (SOC) IN PARTICIPANTS WITH PREVIOUSLY TREATED EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) ( Principal Investigator(PI))
  4. 2025 - 2028, BEIGENE MALAYSIA SDN. BHD
    A PHASE 1A/1B STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF THE CDK4 INHIBITOR BGB-43395, ALONE OR AS PART OF COMBINATION THERAPIES IN PATIENTS WITH METASTATIC HR+/HER2- BREAST CANCER AND OTHER ADVANCED SOLID TUMORS ( Co-Researcher)
  5. 2024 - 2027, FORMYCON AG
    A MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL TO DEMONSTRATE SIMILAR EFFICACY, SAFETY, AND IMMUNOGENICITY OF FYB206 (KEYTRUDA BIOSIMILAR CANDIDATE) IN COMPARISON TO KEYTRUDA (PEMBROLIZUMAB) AS AN ADD-ON TO CHEMOTHERAPY IN TREATMENT-NA VE PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (LOTUS) ( Principal Investigator(PI))
  6. 2022 - 2026, ASTRAZENECA SDN. BHD.
    A PHASE IB MULTICENTER, OPEN-LABEL DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TRASTUZUMAB DERUXTECAN (T-DXD) AND DURVALUMAB IN COMBINATION WITH CISPLATIN, CARBOPLATIN OR PEMETREXED IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 OVEREXPRESSION (HER2+) (DESTINY-LUNG03) ( Principal Investigator(PI))
University
  1. 2025 - 2027, Bantuan Khas Penyelidikan (BKP Special)
    Mapping and Rebuilding Colorectal Cancer Tumour Environments to Improve Treatment Response ( Co-Researcher)
  2. 2025 - 2027, Bantuan Khas Penyelidikan (BKP Special)
    Combining cfDNA Fragmentomics and Methylation Signatures for Non-Invasive Detection of Head and Neck Cancer ( Principal Investigator(PI))

PAPER PRESENTED

PLENARY SPEAKER
  1. Management of advanced lung cancer: without driver mutation, Lung Cancer : Back to basics, University Malaya Medical Centre (National) (08 Nov 2025 - 08 Nov 2025)
  2. Management of Stage III Lung Cancer, Lung Cancer : Back to Basics, University Malaya Medical Centre (National) (08 Nov 2025 - 08 Nov 2025)
  3. Alkylating Agents and antimetabolites, MASTERCLASS IN SYSTEMIC THERAPY 2025, UM, Clinical Oncology Department UM (National) (16 Aug 2025 - 17 Aug 2025)
  4. Beyond the First Fight, Novartis OncoTalk- Understanding the Risk of Recurrence in HR+ HER2- early breast cancer., Novartis Malaysia (University) (06 Jun 2025 - 06 Jun 2025)
INVITED SPEAKER
  1. BREAKING BAD NEWS, LANGUAGE THE HEALS AND NOT HURT, Pink October Forum 2025, United by Unique, Breast Cancer Resource Centre, Universiti Malaya Medical Centre. (University) (06 Oct 2025 - 06 Oct 2025)
ORAL PRESENTER
  1. When Love Demands More: Cultural Pressures Behind Aggressive End-of-Life Chemotherapy in Malaysia, National Cancer Congress 2025, National Cancer Congress Malaysia (International) (19 Jun 2025 - 21 Jun 2025)
POSTER PRESENTER
  1. AGGRESSIVENESS OF END OF LIFE CHEMOTHERAPY WHERE DO WE STAND?, Annual Scientific Congress of Malaysian Oncological Society ASCOMOS, Malaysian Oncology Society (National) (26 Sep 2025 - 28 Sep 2025)

ACADEMIC/ PROF. SERVICES

Evaluation
  1. (2026) Evaluator of Clinical Oncology Program, National, (External Evaluator)
  2. (2026) Evaluator of Clinical Oncology Program, National, (External Evaluator)
  3. (2025) Towards Equitable Cancer Care: a National Registry and Survey of Services and Research Capacity in Malaysia, National, (Reviewer)
  4. (2025) Masters of Clinical Oncology Part 2 November Examination, University, (Internal Examiner)
  5. (2025) Masters of Clinical Oncology Part 1 Examination Nov 2025, University, (Internal Examiner)
  6. (2025) Data Quality Manager, University, (Reviewer)
  7. (2025) Master of Clinical Oncology Final Examination, University, University, (Reviewer)
  8. (2025) Master of Clinical Oncology Part 1 Examination, University, (Internal Examiner)
  9. (2025) Clinical Supervisor and Academic Advisor or Bachelor of Science Nursing Semester Ii 2024/2025, University, (External Examiner)
Media appearance
  1. (2025) Microplastics and Its Effects On Cancer- Social Media Post for Awareness, National, (Panelist/Moderator)
Mentoring
  1. (2025) Clinical Supervisor and Academic Advisor or Bachelor of Science Nursing Semester Ii 2024/2025, University, (Academic Advisor)

COURSE ATTENDED

Internal/ External Course
  1. FOM INTERNAL AUDIT WORKSHOP 2025, THE GALLERY, FACULTY OF MEDICINE, UNIVERSITI MALAYA (01 Jul 2025 - 01 Jul 2025)
  2. EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY ANNUAL CONGRESS, MESSE WIEN EXHIBITION AND CONGRESS CENTER, VIENNA, AUSTRIA (01 May 2025 - 07 May 2025)
External Course
INTERNATIONAL
  1. IAEA RAS6098 Regional Training Course on Optimization of Re-irradiation in Palliative Radiotherapy, Hotel Ac by Marriot Kuala Lumpur (12 May 2025 - 16 May 2025)